NEW YORK, March 10, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Mallinckrodt Public Limited Company securities (NYSE:MNK) from November 25, 2014 through January 18, 2017, inclusive (the “Class Period”) of the important March 27, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Mallinckrodt investors under the federal securities laws.
To join the Mallinckrodt class action, go to http://rosenlegal.com/cases-1002.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Mallinckrodt and its Chief Executive Officer, Mark Trudeau, made a series of false and misleading statements and failed to disclose material adverse facts about the long-term sustainability of Mallinckrodt’s monopolistic HP Acthar Gel (“Acthar”) revenues and the exposure of Acthar to reimbursement rates by Medicare and Medicaid. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that Acthar’s monopoly status as the only FDA-approved adrenocorticotropic hormone preparation was the product of unlawful anticompetitive practices and failed to disclose that its increasing reliance on Medicare and Medicaid meant that Mallinckrodt’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for this drug by taxpayers. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 27, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1002.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 



